All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is pleased to present a visual abstract representing key data from the phase II INCB84344-201 trial (NCT01641107) evaluating ponatinib plus prednisone as a firstline treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are aged ≥60 years or considered ineligible for intensive chemotherapy and stem cell transplantation.
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ ALL?
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could ponatinib + blinatumomab...
Too much of a good thing? An in vitro study with dual Src/ABL kinase inhibitor and blinatumomab suggests some combination treatments for Ph+ ALL may not work well together
The most common cytogenic abnormality in adult patients with acute...
Subscribe to get the best content related to ALL delivered to your inbox